32
Participants
Start Date
May 31, 2005
Primary Completion Date
October 31, 2005
Study Completion Date
October 31, 2005
insulin detemir
On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
insulin glargine
On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site, Hanover
Lead Sponsor
Novo Nordisk A/S
INDUSTRY